MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

"I was raised by hippie-dippy parents in Oregon. No vaccines, was born at home, homeschooled for 16 years, etc. I have since ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...